

=> d his

(FILE 'HOME' ENTERED AT 18:13:34 ON 24 MAR 2006)

FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS' ENTERED AT 18:13:45 ON 24 MAR 2006

L1 0 S (17-ODECAYNOIC ACID) (3A) STRUCTURE
L2 0 S (17-ODECENOIC ACID) (3A) STRUCTURE
L3 0 S 17-ODECYNOIC ACID
L4 670 S 17-OCTADECYNOIC ACID
L5 0 S L4 (3A) STRUCTURE
L6 1 S ((OCTADECYNOIC ACID) OR (ODYA)) (3A) STRUCTURE
L7 1 S FEXOFENADINE (P) LACTOSE (P) LOW-SUBSTITUTED HYDROXYPROPYL CE
L8 1 S FEXOFENADINE (P) LACTOSE (P) SUBSTITUTED HYDROXYPROPYL CELLUL
L9 1 S FEXOFENADINE (P) LACTOSE (P) HYDROXYPROPYL CELLULOSE
L10 9 S FEXOFENADINE (P) LACTOSE
L11 3 S FEXOFENADINE (P) HYDROXYPROPYL CELLULOSE

L7 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:136558 CAPLUS
 DOCUMENT NUMBER: 142:225793
 TITLE: A process for preparing fexofenadine composition
 INVENTOR(S): Nandi, Indranil; Patel, Ashish Anilbhai; Sadatrezaei,
 Mohsen; Davila, Pablo; Khanapure, Virendra Maheshappa;
 Durugkar, Surendra Wasudeorao
 PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
 SOURCE: PCT Int. Appl., 31 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005013987	A1	20050217	WO 2004-EP8600	20040730
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005065183	A1	20050324	US 2003-631874	20030731

PRIORITY APPLN. INFO.: US 2003-631874 A 20030731

AB A pharmaceutical composition comprising **fexofenadine** or a pharmaceutically acceptable salt thereof, **lactose**, a low -substituted hydroxypropyl cellulose and optionally other excipients is disclosed. The **fexofenadine** compns. of the invention exhibit improved bioavailability as expressed as Cmax, the maximum amount of active ingredient found in the plasma, or as AUC, the area under the plasma concentration time curve. For example, a **fexofenadine** tablet composition was prepared by wet granulation of a powder blend containing **fexofenadine-HCl** 180 g, **lactose** 348 g, and hydroxypropyl cellulose 30 g. Wet granules were dried and then passed through 20 mesh, blended with crospovidone 36 g, and then with magnesium stearate 6 g. The lubricated granules were then compressed into tablets. The compressed tablets were optionally film coated with a composition containing HPMC 70%, TiO2 19.2%, propylene glycol 10%, yellow iron oxide 0.5%, and red iron oxide 0.3% to a total weight of 618 mg.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:136558 CAPLUS
DOCUMENT NUMBER: 142:225793
TITLE: A process for preparing fexofenadine composition
INVENTOR(S): Nandi, Indranil; Patel, Ashish Anilbhai; Sadatrezaei,
Mohsen; Davila, Pablo; Khanapure, Virendra Maheshappa;
Durugkar, Surendra Wasudeorao
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIIXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005013987	A1	20050217	WO 2004-EP8600	20040730
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005065183	A1	20050324	US 2003-631874	20030731

PRIORITY APPLN. INFO.: US 2003-631874 A 20030731

AB A pharmaceutical composition comprising **fexofenadine** or a pharmaceutically acceptable salt thereof, **lactose**, a low -**substituted hydroxypropyl cellulose** and optionally other excipients is disclosed. The **fexofenadine** compns. of the invention exhibit improved bioavailability as expressed as Cmax, the maximum amount of active ingredient found in the plasma, or as AUC, the area under the plasma concentration time curve. For example, a **fexofenadine** tablet composition was prepared by wet granulation of a powder blend containing **fexofenadine-HCl** 180 g, **lactose** 348 g, and **hydroxypropyl cellulose** 30 g. Wet granules were dried and then passed through 20 mesh, blended with crospovidone 36 g, and then with magnesium stearate 6 g. The lubricated granules were then compressed into tablets. The compressed tablets were optionally film coated with a composition containing HPMC 70%, TiO2 19.2%, propylene glycol 10%, yellow iron oxide 0.5%, and red iron oxide 0.3% to a total weight of 618 mg.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:136558 CAPLUS
 DOCUMENT NUMBER: 142:225793
 TITLE: A process for preparing fexofenadine composition
 INVENTOR(S): Nandi, Indranil; Patel, Ashish Anilbhai; Sadatrezaei,
 Mohsen; Davila, Pablo; Khanapure, Virendra Maheshappa;
 Durugkar, Surendra Wasudeorao
 PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
 SOURCE: PCT Int. Appl., 31 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005013987	A1	20050217	WO 2004-EP8600	20040730
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005065183	A1	20050324	US 2003-631874	20030731

PRIORITY APPLN. INFO.: US 2003-631874 A 20030731

AB A pharmaceutical composition comprising **fexofenadine** or a pharmaceutically acceptable salt thereof, **lactose**, a low -**substituted hydroxypropyl cellulose** and optionally other excipients is disclosed. The **fexofenadine** compns. of the invention exhibit improved bioavailability as expressed as Cmax, the maximum amount of active ingredient found in the plasma, or as AUC, the area under the plasma concentration time curve. For example, a **fexofenadine** tablet composition was prepared by wet granulation of a powder blend containing **fexofenadine-HCl** 180 g, **lactose** 348 g, and **hydroxypropyl cellulose** 30 g. Wet granules were dried and then passed through 20 mesh, blended with crospovidone 36 g, and then with magnesium stearate 6 g. The lubricated granules were then compressed into tablets. The compressed tablets were optionally film coated with a composition containing HPMC 70%, TiO2 19.2%, propylene glycol 10%, yellow iron oxide 0.5%, and red iron oxide 0.3% to a total weight of 618 mg.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 1 OF 9 MEDLINE on STN
ACCESSION NUMBER: 2005238475 MEDLINE
DOCUMENT NUMBER: PubMed ID: 15875527
TITLE: The efficacy of short-term administration of 3
antihistamines vs placebo under natural exposure to
Japanese cedar pollen.
AUTHOR: Hyo Sawako; Fujieda Shigeharu; Kawada Ryo; Kitazawa
Shikifumi; Takenaka Hiroshi
CORPORATE SOURCE: Department of Otorhinolaryngology, Osaka Medical College,
Osaka, Japan.. oto039@poh.osaka-med.ac.jp
SOURCE: Annals of allergy, asthma & immunology : official
publication of the American College of Allergy, Asthma, &
Immunology, (2005 Apr) Vol. 94, No. 4, pp. 457-64.
Journal code: 9503580. ISSN: 1081-1206.
PUB. COUNTRY: United States
DOCUMENT TYPE: (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200505
ENTRY DATE: Entered STN: 20050510
Last Updated on STN: 20050525
Entered Medline: 20050524
AB BACKGROUND: Japanese cedar pollinosis, a common disease with morbidity of approximately 20% in the Japanese population, is characterized by subjectively irritating symptoms during an annual 3-month period.
OBJECTIVE: To investigate the effectiveness of cetirizine hydrochloride, loratadine, and **fexofenadine** hydrochloride in reducing pollinosis symptoms induced while walking in a park during the pollen season. METHODS: A randomized, double-masked, placebo-controlled trial was conducted in 113 individuals with Japanese cedar pollinosis during 2 days in March 2003 in Osaka Expo Park, Osaka, Japan. Participants (aged 20-57 years) were divided into 4 groups according to treatment assignment: cetirizine hydrochloride, 10 mg/d; **fexofenadine** hydrochloride, 120 mg/d; loratadine, 10 mg/d; and placebo (**lactose**), twice daily. Symptoms were recorded hourly during the study. Furthermore, all the patients completed the Japanese version of the Rhinoconjunctivitis Quality of Life Questionnaire before and after the trial. RESULTS: Self-evaluated symptom scores in all 3 active treatment groups showed significant improvements compared with the placebo group. Furthermore, the cetirizine group showed significant improvement in the domains of frequency of nose blowing and nasal obstruction compared with placebo. In addition, improvement in Japanese Rhinoconjunctivitis Quality of Life Questionnaire scores was higher in the cetirizine group than in the loratadine and placebo groups. CONCLUSION: Cetirizine seems to be more effective than **fexofenadine** and loratadine at reducing subjective symptoms in this study population.

L10 ANSWER 2 OF 9 EMBASE COPYRIGHT (c) 2006 Elsevier B.V. All rights reserved on STN
ACCESSION NUMBER: 2005183746 EMBASE
TITLE: The efficacy of short-term administration of 3
antihistamines vs placebo under natural exposure to
Japanese cedar pollen.
AUTHOR: Hyo S.; Fujieda S.; Kawada R.; Kitazawa S.; Takenaka H.
CORPORATE SOURCE: Dr. S. Hyo, 2-7 Digaku-chou, Takatsuki city, Osaka
569-8686, Japan. oto039@poh.osaka-med.ac.jp
SOURCE: Annals of Allergy, Asthma and Immunology, (2005) Vol. 94,
No. 4, pp. 457-464. .
Refs: 36
ISSN: 1081-1206 CODEN: ALAIF6
COUNTRY: United States

DOCUMENT TYPE: Journal; Article
FILE SEGMENT: 006 Internal Medicine
026 Immunology, Serology and Transplantation
037 Drug Literature Index
038 Adverse Reactions Titles

LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 20050526
Last Updated on STN: 20050526

AB Background: Japanese cedar pollinosis, a common disease with morbidity of approximately 20% in the Japanese population, is characterized by subjectively irritating symptoms during an annual 3-month period. Objective: To investigate the effectiveness of cetirizine hydrochloride, loratadine, and **fexofenadine** hydrochloride in reducing pollinosis symptoms induced while walking in a park during the pollen season. Methods: A randomized, double-masked, placebo-controlled trial was conducted in 113 individuals with Japanese cedar pollinosis during 2 days in March 2003 in Osaka Expo Park, Osaka, Japan. Participants (aged 20-57 years) were divided into 4 groups according to treatment assignment: cetirizine hydrochloride, 10 mg/d; **fexofenadine** hydrochloride, 120 mg/d; loratadine, 10 mg/d; and placebo (**lactose**), twice daily. Symptoms were recorded hourly during the study. Furthermore, all the patients completed the Japanese version of the Rhinoconjunctivitis Quality of Life Questionnaire before and after the trial. Results: Self-evaluated symptom scores in all 3 active treatment groups showed significant improvements compared with the placebo group. Furthermore, the cetirizine group showed significant improvement in the domains of frequency of nose blowing and nasal obstruction compared with placebo. In addition, improvement in Japanese Rhinoconjunctivitis Quality of Life Questionnaire scores was higher in the cetirizine group than in the loratadine and placebo groups. Conclusion: Cetirizine seems to be more effective than **fexofenadine** and loratadine at reducing subjective symptoms in this study population.

L10 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:611930 CAPLUS
DOCUMENT NUMBER: 143:139149
TITLE: Oral pharmaceutical compositions
INVENTOR(S): Mungre, Ashish Prabhakar; Nabar, Manisha Saiprasad
PATENT ASSIGNEE(S): Sun Pharmaceutical Industries Limited, India
SOURCE: PCT Int. Appl., 17 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005062722	A2	20050714	WO 2004-IN362	20041122
WO 2005062722	A3	20050922		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: IN 2003-MU1204 A 20031121
AB The present invention provides an immediate release oral pharmaceutical

composition comprising **fexofenadine** or its salts, a dissoln. enhancing amount of a thermomelting binding agent and excipients. Tablets contained **fexofenadine-HCl** 30.0, lactose 50.0, Prosolv SMCC-90 17.5, SLS 1.0, colloidal silica 0.5, and Mg stearate 1.0%.

L10 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:430016 CAPLUS
DOCUMENT NUMBER: 143:109441
TITLE: The efficacy of short-term administration of 3 antihistamines vs. placebo under natural exposure to Japanese cedar pollen
AUTHOR(S): Hyo, Sawako; Fujieda, Shigeharu; Kawada, Ryo; Kitazawa, Shikifumi; Takenaka, Hiroshi
CORPORATE SOURCE: Department of Otorhinolaryngology, Osaka Medical College, Osaka, Japan
SOURCE: Annals of Allergy, Asthma, & Immunology (2005), 94(4), 457-464
CODEN: ALAIF6; ISSN: 1081-1206
PUBLISHER: American College of Allergy, Asthma, & Immunology
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Japanese cedar pollinosis, a common disease with morbidity of approx. 20% in the Japanese population, is characterized by subjectively irritating symptoms during an annual 3-mo period. The aim was to investigate the effectiveness of cetirizine hydrochloride, loratadine, and **fexofenadine** hydrochloride in reducing pollinosis symptoms induced while walking in a park during the pollen season. A randomized, double-masked, placebo-controlled trial was conducted in 113 individuals with Japanese cedar pollinosis during 2 days in Mar. 2003 in Osaka Expo Park, Osaka, Japan. Participants (aged 20-57 years) were divided into 4 groups according to treatment assignment: cetirizine hydrochloride, 10 mg/d; **fexofenadine** hydrochloride, 120 mg/d; loratadine, 10 mg/d; and placebo (lactose), twice daily. Symptoms were recorded hourly during the study. Furthermore, all the patients completed the Japanese version of the Rhinoconjunctivitis Quality of Life Questionnaire before and after the trial. Self-evaluated symptom scores in all 3 active treatment groups showed significant improvements compared with the placebo group. Furthermore, the cetirizine group showed significant improvement in the domains of frequency of nose blowing and nasal obstruction compared with placebo. In addition, improvement in Japanese Rhinoconjunctivitis Quality of Life Questionnaire scores was higher in the cetirizine group than in the loratadine and placebo groups. Cetirizine seems to be more effective than **fexofenadine** and loratadine at reducing subjective symptoms in this study population.

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:219717 CAPLUS
DOCUMENT NUMBER: 142:266844
TITLE: Orosoluble tablets containing fexofenadine
INVENTOR(S): Faham, Amina; Marechal, Dominique; Chenevier, Philippe
PATENT ASSIGNEE(S): Can.
SOURCE: U.S. Pat. Appl. Publ., 11 pp., Cont.-in-part of U.S. Ser. No. 995,975.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005053654	A1	20050310	US 2004-495007	20041025

US 2003099700	A1	20030529	US 2001-995975	20011116
US 6723348	B2	20040420		
WO 2003041683	A2	20030522	WO 2002-EP14917	20021114
WO 2003041683	A3	20030828		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-995975 A2 20011116
 WO 2002-EP14917 W 20021114

AB Orodispersible tablets disintegrate in the buccal cavity upon contact with saliva by the formation of an easy-to-swallow suspension, in <60 s, preferably in <40 s, containing fexofenadine in coated granules, and a mixture of excipients. The formulation also comprises at least 1 disintegrant, a soluble diluent, a lubricant and optionally a swelling agent, sweeteners, flavoring agents and colors; the process for obtaining such orodispersible tablets and the coated granules incorporated therein and the use of the orodispersible tablets in the treatment of seasonal allergic rhinitis. Thus, 500 g fexofenadine-HCl was mixed with 15 g Syloid FP244 and granulated with a mixture of Eudragit EPO/Eudragit NE30D in water at 16%.

L10 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:136558 CAPLUS
 DOCUMENT NUMBER: 142:225793
 TITLE: A process for preparing fexofenadine composition
 INVENTOR(S): Nandi, Indranil; Patel, Ashish Anilbhai; Sadatrezaei, Mohsen; Davila, Pablo; Khanapure, Virendra Maheshappa; Durugkar, Surendra Wasudeorao
 PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
 SOURCE: PCT Int. Appl., 31 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005013987	A1	20050217	WO 2004-EP8600	20040730
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

US 2005065183 A1 20050324 US 2003-631874 20030731

PRIORITY APPLN. INFO.: US 2003-631874 A 20030731

AB A pharmaceutical composition comprising fexofenadine or a pharmaceutically acceptable salt thereof, lactose, a low-substituted hydroxypropyl cellulose and optionally other excipients is disclosed. The fexofenadine compns. of the invention exhibit improved bioavailability as expressed as Cmax, the maximum amount of active ingredient found in the plasma, or as AUC, the area under the plasma

concentration time curve. For example, a fexofenadine tablet composition was prepared by wet granulation of a powder blend containing fexofenadine-HCl 180 g, lactose 348 g, and hydroxypropyl cellulose 30 g. Wet granules were dried and then passed through 20 mesh, blended with crospovidone 36 g, and then with magnesium stearate 6 g. The lubricated granules were then compressed into tablets. The compressed tablets were optionally film coated with a composition containing HPMC 70%,

TiO₂

19.2%, propylene glycol 10%, yellow iron oxide 0.5%, and red iron oxide 0.3% to a total weight of 618 mg.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2003:396696 CAPLUS
 DOCUMENT NUMBER: 138:390960
 TITLE: Orodispersible tablets containing fexofenadine
 INVENTOR(S): Faham, Amina; Marechal, Dominique; Chenevier, Philippe
 PATENT ASSIGNEE(S): Ethypharm, Fr.
 SOURCE: PCT Int. Appl., 33 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003041683	A2	20030522	WO 2002-EP14917	20021114
WO 2003041683	A3	20030828		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003099700	A1	20030529	US 2001-995975	20011116
US 6723348	B2	20040420		
CA 2466580	AA	20030522	CA 2002-2466580	20021114
EP 1458387	A2	20040922	EP 2002-803040	20021114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005513008	T2	20050512	JP 2003-543570	20021114
US 2005053654	A1	20050310	US 2004-495007	20041025
PRIORITY APPLN. INFO.:			US 2001-995975	A 20011116
			WO 2002-EP14917	W 20021114

AB The present invention concerns orodispersible tablets, which are able to disintegrate in the buccal cavity upon contact with saliva by formation of an easy-to-swallow suspension, in less than 60 s, preferably in less than 40 s, containing fexofenadine in the form of coated granules, and a mixture of excipients comprising at least one disintegrating agent, a soluble diluent agent, a lubricant and optionally a swelling agent, a permeabilizing agent, sweeteners, flavoring agents and colors; the process for obtaining such orodispersible tablets and the coated granules incorporated therein and the use of said orodispersible tablets in the treatment of seasonal allergic rhinitis. Granules were prepared containing fexofenadine-HCl, Syloid FP 244, Eudragit EPO and Eudragit NE30 D. The granules were coated with a mixture of Eudragit EPO/Eudragit NE30D (50:50) and the dissoln. rates of the coated granules were determined

L10 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:833069 CAPLUS
 DOCUMENT NUMBER: 135:376743
 TITLE: Packaging regimen of pseudoephedrine and fexofenadine
 INVENTOR(S): Randall, Douglas E.; Nicholas, James M.
 PATENT ASSIGNEE(S): Aventis Pharmaceuticals Inc., USA
 SOURCE: PCT Int. Appl., 27 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001085148	A2	20011115	WO 2001-US14353	20010503
WO 2001085148	A3	20020801		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001061165	A5	20011120	AU 2001-61165	20010503
US 2002022639	A1	20020221	US 2001-848463	20010503
JP 2003532671	T2	20031105	JP 2001-581802	20010503
PRIORITY APPLN. INFO.:			US 2000-202323P	P 200000505
			GB 2000-30802	A 20001218
			WO 2001-US14353	W 20010503

AB A package for dispensing 2 or more drugs is described and claimed. In one of the embodiments of this invention, the package dispenses essentially: a container to dispense drug (A) having therapeutically effective amts. of fexofenadine or its salt; and a container to dispense drug (B) containing a combination of fexofenadine and pseudoephedrine or their salts. Various preferred embodiments of the package of this invention are also described and claimed. Thus, the package of a bilayer tablet comprises a first discrete zone containing 25-33% pseudoephedrine, and a first carrier base material. The first carrier base material comprises a mixture of carnauba wax 66-74% and a suitable antiadherent 0.50-1.50 by weight of pseudoephedrine.

L10 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:228702 CAPLUS
 DOCUMENT NUMBER: 134:242705
 TITLE: Preparation of controlled drug delivery system containing pseudoephedrine and a long acting antihistamine
 INVENTOR(S): Jain, Girish Kumar; Rampal, Ashok; Sen, Himadri
 PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
 SOURCE: PCT Int. Appl., 27 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021168	A1	20010329	WO 2000-IB1315	20000918
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,				

HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
US 6267986 B1 20010731 US 1999-405643 19990924
EP 1217997 A1 20020703 EP 2000-958919 20000918
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL
PRIORITY APPLN. INFO.: US 1999-405643 A 19990924
WO 2000-IB1315 W 20000918

AB This invention relates to a process for the preparation of a controlled release pharmaceutical composition comprising 2 discrete zones wherein the first discrete zone comprises therapeutically effective amount of pseudoephedrine or its pharmaceutically acceptable salt as active ingredient and the second discrete zone comprises a therapeutically effective amount of a long-acting antihistamine selected from the group consisting of loratadine, azatadine, **fexofenadine**, terfenadine, cetirizine, astemizole, and levocabastine, or their pharmaceutically acceptable salt as active ingredient. Thus, the first tablet layer was formed from pseudoephedrine sulfate 40.00, Keltrol TF 33.33, Keltone HVCR 13.33, CaCO₃ 8.83, Mg stearate 1.00, and Aerosil-200 1.00%. The second tablet layer was obtained from loratadine 5.00, lactose 47.50, Avicel PH-101 33.25, FD&C-10 0.50, corn starch 10.00, starch (for paste) 3.00, and Mg stearate 0.75% by weight. The 2 layers were compressed into tablets.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:219717 CAPLUS
 DOCUMENT NUMBER: 142:266844
 TITLE: Orodispersible tablets containing fexofenadine
 INVENTOR(S): Faham, Amina; Marechal, Dominique; Chenevier, Philippe
 PATENT ASSIGNEE(S): Can.
 SOURCE: U.S. Pat. Appl. Publ., 11 pp., Cont.-in-part of U.S.
 Ser. No. 995,975.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005053654	A1	20050310	US 2004-495007	20041025
US 2003099700	A1	20030529	US 2001-995975	20011116
US 6723348	B2	20040420		
WO 2003041683	A2	20030522	WO 2002-EP14917	20021114
WO 2003041683	A3	20030828		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			US 2001-995975	A2 20011116
			WO 2002-EP14917	W 20021114

AB Orodispersible tablets disintegrate in the buccal cavity upon contact with saliva by the formation of an easy-to-swallow suspension, in <60 s, preferably in <40 s, containing fexofenadine in coated granules, and a mixture of excipients. The formulation also comprises at least 1 disintegrant, a soluble diluent, a lubricant and optionally a swelling agent, sweeteners, flavoring agents and colors; the process for obtaining such orodispersible tablets and the coated granules incorporated therein and the use of the orodispersible tablets in the treatment of seasonal allergic rhinitis. Thus, 500 g fexofenadine-HCl was mixed with 15 g Syloid FP244 and granulated with a mixture of Eudragit EPO/Eudragit NE30D in water at 16%.

L11 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2005:136558 CAPLUS
 DOCUMENT NUMBER: 142:225793
 TITLE: A process for preparing fexofenadine composition
 INVENTOR(S): Nandi, Indranil; Patel, Ashish Anilbhai; Sadatrezaei,
Mohsen; Davila, Pablo; Khanapure, Virendra Maheshappa;
Durugkar, Surendra Wasudeorao
 PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
 SOURCE: PCT Int. Appl., 31 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005013987	A1	20050217	WO 2004-EP8600	20040730
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,			

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

US 2005065183 A1 20050324 US 2003-631874 20030731

PRIORITY APPLN. INFO.: US 2003-631874 A 20030731

AB A pharmaceutical composition comprising **fexofenadine** or a pharmaceutically acceptable salt thereof, lactose, a low-substituted **hydroxypropyl cellulose** and optionally other excipients is disclosed. The **fexofenadine** compns. of the invention exhibit improved bioavailability as expressed as Cmax, the maximum amount of active ingredient found in the plasma, or as AUC, the area under the plasma concentration time curve. For example, a **fexofenadine** tablet composition was prepared by wet granulation of a powder blend containing **fexofenadine-HCl** 180 g, lactose 348 g, and **hydroxypropyl cellulose** 30 g. Wet granules were dried and then passed through 20 mesh, blended with crospovidone 36 g, and then with magnesium stearate 6 g. The lubricated granules were then compressed into tablets. The compressed tablets were optionally film coated with a composition containing

HPMC

70%, TiO₂ 19.2%, propylene glycol 10%, yellow iron oxide 0.5%, and red iron oxide 0.3% to a total weight of 618 mg.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:396696 CAPLUS

DOCUMENT NUMBER: 138:390960

TITLE: Orodispersible tablets containing fexofenadine

INVENTOR(S): Faham, Amina; Marechal, Dominique; Chenevier, Philippe

PATENT ASSIGNEE(S): Ethypharm, Fr.

SOURCE: PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003041683	A2	20030522	WO 2002-EP14917	20021114
WO 2003041683	A3	20030828		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003099700	A1	20030529	US 2001-995975	20011116
US 6723348	B2	20040420		
CA 2466580	AA	20030522	CA 2002-2466580	20021114
EP 1458387	A2	20040922	EP 2002-803040	20021114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				

JP 2005513008	T2	20050512	JP 2003-543570	20021114
US 2005053654	A1	20050310	US 2004-495007	20041025
PRIORITY APPLN. INFO.:			US 2001-995975	A 20011116
			WO 2002-EP14917	W 20021114

AB The present invention concerns orodispersible tablets, which are able to disintegrate in the buccal cavity upon contact with saliva by formation of an easy-to-swallow suspension, in less than 60 s, preferably in less than 40 s, containing fexofenadine in the form of coated granules, and a mixture of excipients comprising at least one disintegrating agent, a soluble diluent agent, a lubricant and optionally a swelling agent, a permeabilizing agent, sweeteners, flavoring agents and colors; the process for obtaining such orodispersible tablets and the coated granules incorporated therein and the use of said orodispersible tablets in the treatment of seasonal allergic rhinitis. Granules were prepared containing fexofenadine-HCl, Syloid FP 244, Eudragit EPO and Eudragit NE30 D. The granules were coated with a mixture of Eudragit EPO/Eudragit NE30D (50:50) and the dissoln. rates of the coated granules were determined